

# CITATION REPORT

List of articles citing

## Therapeutic goals in the treatment of Gaucher disease

DOI: 10.1053/j.seminhematol.2004.07.009  
Seminars in Hematology, 2004, 41, 4-14.

**Source:** <https://exaly.com/paper-pdf/37583587/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
394	Thrombotic Thrombocytopenic Purpura and ADAMTS-13: New Insights into Pathogenesis, Diagnosis, and Therapy. <b>2004</b> , 35, 733-739		2
393	Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. <i>Seminars in Hematology</i> , <b>2004</b> , 41, 15-22	4	178
392	Bibliography. Current world literature. Hemostasis and thrombosis. <b>2004</b> , 11, 205-42		
391	Bibliography Current World Literature. <b>2005</b> , 12, 153-196		1
390	Recent clinical progress in Gaucher disease. <b>2005</b> , 17, 519-24		47
389	The role of endothelial cell apoptosis in inflammatory and immune diseases. <b>2005</b> , 3, 1815-24		113
388	Gaucher disease: pathological mechanisms and modern management. <i>British Journal of Haematology</i> , <b>2005</b> , 129, 178-88	4.5	203
387	Evaluation of platelet function under high shear condition in the small-sized collagen bead column. <b>2005</b> , 146, 64-75		10
386	Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis. <b>2005</b> , 34, 683-8		45
385	Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. <i>American Journal of Hematology</i> , <b>2005</b> , 80, 223-9	7.1	74
384	Treatment. 297-323		
383	Thérapies enzymatiques substitutives des maladies lysosomales. <b>2005</b> , 21, 77-83		3
382	Atherothrombotic disorders: new insights from hematology. <b>2005</b> , 111, 1855-63		40
381	Individualization of long-term enzyme replacement therapy for Gaucher disease. <i>Genetics in Medicine</i> , <b>2005</b> , 7, 105-10	8.1	88
380	Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. <b>2005</b> , 31, 659-72		35
379	High clotting factor activities and enhanced platelet-related haemostasis in a patient with recurrent episodes of thrombotic-thrombocytopenic purpura: additional risk factors for onset and recurrence?. <b>2005</b> , 20, 1515-6		1
378	An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. <b>2005</b> , 27, 1215-27		113

377	The "cutting" edge: von Willebrand factor-cleaving protease activity in thrombotic microangiopathies. <b>2005</b> , 32, 177-84	5
376	Purpura thrombotique thrombocytopénique et autres syndromes de microangiopathie thrombotique. <b>2005</b> , 2, 14-34	8
375	Ultrastructural features of gaucher disease treated with enzyme replacement therapy presenting as mesenteric mass lesions. <b>2006</b> , 25, 241-8	11
374	Recommandations internationales concernant l'évaluation initiale et le suivi des patients adultes atteints de maladie de Gaucher de type 1. <b>2006</b> , 35, 10-12	
373	Les complications osseuses dans la maladie de Gaucher. <b>2006</b> , 35, 15-18	1
372	Clinical use of plasma and plasma fractions. <b>2006</b> , 19, 83-96	23
371	Stop-codon read-through for patients affected by a lysosomal storage disorder. <b>2006</b> , 12, 367-73	71
370	Thrombotic thrombocytopenic purpura and systemic lupus erythematosus - distinct entities or overlapping syndromes?. <b>2006</b> , 34, 263-6	9
369	MMPs and ADAMTSs: functional studies. <b>2006</b> , 11, 544-69	65
368	Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. <b>2006</b> , 108, 830-5	115
367	Purpura thrombotique thrombocytopénique et autres syndromes de microangiopathie thrombotique. <b>2006</b> , 1, 1-15	
366	A rapid enzyme-linked assay for ADAMTS-13. <b>2006</b> , 4, 129-36	33
365	ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. <b>2006</b> , 4, 955-62	75
364	Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. <b>2006</b> , 29, 92-8	36
363	Pathophysiologie, Diagnostik und Therapie - Thrombotisch-thrombo-zytopenische Purpura und hämolytisch-urämisches Syndrom. <b>2006</b> , 35, 368-374	
362	Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. <b>2006</b> , 103, 18470-4	54
361	Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. <b>2006</b> , 22, 1045-64	69
360	The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. <b>2006</b> , 160, 603-8	140

359	Delivery of lysosomal enzymes for therapeutic use: glucocerebrosidase as an example. <b>2006</b> , 3, 771-82		18
358	Agalsidase alfa therapy for Fabry disease. <b>2007</b> , 2, 147-154		1
357	Emerging technologies in hemostasis diagnostics: a report from the Australasian Society of Thrombosis and Haemostasis Emerging Technologies Group. <b>2007</b> , 33, 226-34		15
356	Therapeutic Goals in the Treatment of Gaucher Disease. <b>2007</b> , 345-370		
355	Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. <b>2007</b> , 110, 2296-301		92
354	Hyperimmunoglobulinemia in pediatric-onset type 1 Gaucher disease and effects of enzyme replacement therapy. <b>2007</b> , 29, 451-7		19
353	Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias. <b>2007</b> , 14, 647-54		17
352	Enzyme reconstitution/replacement therapy for lysosomal storage diseases. <b>2007</b> , 19, 628-35		43
351	The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. <i>Molecular Genetics and Metabolism</i> , <b>2007</b> , 91, 37-47	3.7	148
350	The outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapy. <i>Molecular Genetics and Metabolism</i> , <b>2007</b> , 92, 131-6	3.7	9
349	Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. <b>2007</b> , 1772, 788-96		79
348	A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , <b>2007</b> , 39, 115-8	2.1	45
347	Rash and neurological symptoms. <b>2007</b> , 32, 299-303		3
346	[Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment]. <b>2007</b> , 36, 1971-84		6
345	Comprehensive Disease Management Model in Heterogeneous Progressive Disease, Exemplified by Gaucher Disease. <b>2007</b> , 29, S79-S80		
344	The Bone in Gaucher Disease. <b>2007</b> , 29, S91-S92		
343	[Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment]. <i>Revue De Medecine Interne</i> , <b>2007</b> , 28 Suppl 2, S180-2	0.1	1
342	[Gaucher disease in childhood]. <i>Revue De Medecine Interne</i> , <b>2007</b> , 28 Suppl 2, S183-6	0.1	8

341	Lysosomal Storage Disorders. <b>2007</b> ,		7
340	Oral aspects of Gaucher's disease: a literature review and case report. <b>2007</b> , 78, 783-8		16
339	Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. <i>American Journal of Hematology</i> , <b>2007</b> , 82, 697-701	7.1	94
338	Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. <b>2007</b> , 71, 576-88		73
337	Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. <i>British Journal of Haematology</i> , <b>2007</b> , 138, 676-86	4.5	73
336	Consensus recommendations. <i>British Journal of Haematology</i> , <b>2007</b> , 138, 673-5	4.5	2
335	Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. <b>2007</b> , 5, 321-8		45
334	Thrombotic thrombocytopenic purpura-like thrombocytopenia closely related to uremia: report of two cases. <b>2007</b> , 11, 382-6		2
333	Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. <b>2007</b> , 151, 197-201		38
332	[Cost reduction in the treatment of Gaucher s disease]. <b>2007</b> , 31, 194-5		
331	Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience. <b>2007</b> , 30, 783-9		12
330	Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. <b>2008</b> , 31, 319-36		94
329	Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat. <b>2008</b> , 83, 43-54		20
328	A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. <i>American Journal of Hematology</i> , <b>2008</b> , 83, 890-5	7.1	63
327	Using the International Gaucher Disease Registry data: can we devise a virtuous circle for treated patients?. <i>American Journal of Hematology</i> , <b>2008</b> , 83, 887-9	7.1	2
326	Recombinant therapeutic proteins: production platforms and challenges. <b>2008</b> , 3, 90-7		112
325	Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. <b>2008</b> , 73, 430-40		94
324	von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). <b>2008</b> , 14, 171-232		676

323	Gaucher disease: unmet treatment needs. <b>2008</b> , 97, 83-7		11
322	[Neurological manifestations in patients with Gaucher disease and in their relatives]. <b>2008</b> , 131, 175-9		3
321	[Comment on the editorial: Lysosomal storage diseases. Is a modification in the natural course of disease being produced?]. <b>2008</b> , 131, 636; author reply 636-7		
320	Imiglucerase and its use for the treatment of Gaucher's disease. <b>2008</b> , 9, 1987-2000		35
319	Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic intervention. <i>Blood Cells, Molecules, and Diseases</i> , <b>2008</b> , 40, 420-7	2.1	23
318	Phenotype, diagnosis, and treatment of Gaucher's disease. <b>2008</b> , 372, 1263-71		409
317	Successful treatment of thrombotic thrombocytopenic purpura with repeated plasma exchange in a patient with microscopic polyangiitis. <b>2008</b> , 18, 643-646		12
316	Histiocytic and Dendritic Cell Disorders. <b>2008</b> , 489-512		1
315	Hypercoagulable states in cardiovascular disease. <b>2008</b> , 118, 2286-97		93
314	Therapeutic options for childhood-onset lysosomal storage disorders. <b>2008</b> , 2, 21-32		1
313	A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. <b>2008</b> , 93, 1211-8		45
312	Avaliaç�o de dois anos de tratamento da doena de Gaucher tipo 1 com terapia de reposio enzim�tica em pacientes do estado de S�o Paulo, Brasil. <b>2008</b> , 30,		2
311	The emerging roles of ADAMTS-7 and ADAMTS-12 matrix metalloproteinases. <b>2009</b> , 1, 121-131		9
310	Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. <i>Biologics: Targets and Therapy</i> , <b>2009</b> , 407	4.4	6
309	Thrombotic thrombocytopenic purpura: the masquerader. <b>2009</b> , 102, 504-9		7
308	L'approche h�matologique de la maladie de Gaucher. <b>2009</b> , 15, 272-280		
307	Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships. <b>2009</b> , 10, 2641-52		21
306	Goal-oriented therapy with miglustat in Gaucher disease. <b>2009</b> , 25, 23-37		32

305	Acid beta-glucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipid. <b>2009</b> , 284, 12979-88		44
304	Enzyme replacement therapy for Gaucher disease. <b>2009</b> , 9, 121-31		30
303	Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. <b>2009</b> , 155, S10-8		37
302	Enzyme replacement therapy for mild patients with Gaucher disease. <i>American Journal of Hematology</i> , <b>2009</b> , 84, 202-4	7.1	21
301	Management of neuronopathic Gaucher disease: revised recommendations. <b>2009</b> , 32, 660-664		78
300	Alpha versus beta: are we on the way to resolve the mystery as to which is the endogenous ligand for natural killer T cells?. <b>2009</b> , 158, 300-7		15
299	Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent. <b>2009</b> , 87, 514-24		27
298	The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). <i>Blood Cells, Molecules, and Diseases</i> , <b>2009</b> , 43, 264-88 <sup>2.1</sup>		44
297	Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?. <i>Molecular Genetics and Metabolism</i> , <b>2009</b> , 96, 73-6	3.7	4
296	D'couverte d'ne schizocytose circulante': orientation diagnostique. <b>2009</b> , 24, 261-266		
295	Gaucher's Disease. <b>2009</b> , 520-528		1
294	Encyclopedia of Molecular Mechanisms of Disease. <b>2009</b> , 2172-2172		
293	Pregnancy with Crigler-Najjar syndrome type II. <b>2009</b> , 29, 242-4		5
292	Gaucher disease and pregnancy. <b>2009</b> , 29, 240-2		1
291	[Gaucher disease and pregnancy]. <b>2009</b> , 38 Suppl 2, 2S17-23		0
290	[Gaucher disease in children]. <b>2009</b> , 38 Suppl 2, 2S24-7		
289	[Diagnosis of type 1 Gaucher disease: follow-up in internal medicine, disease course aspects in 17 years]. <b>2009</b> , 38 Suppl 2, 2S61-4		
288	[Benefits of early enzyme replacement therapy in two children with type 1 Gaucher disease]. <b>2009</b> , 38 Suppl 2, 2S65-7		

287	A review of the ADAMTS family, pharmaceutical targets of the future. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 2359-74	3-3	58
286	Production of recombinant human von Willebrand factor in the milk of transgenic pigs. <b>2009</b> , 55, 484-90		15
285	Blood coagulation: hemostasis and thrombin regulation. <b>2009</b> , 108, 1433-46		234
284	Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. <b>2009</b> , 94, 1771-5		55
283	Successful treatment with rituximab in a patient with TTP secondary to severe ANCA-associated vasculitis. <i>Internal Medicine</i> , <b>2010</b> , 49, 1587-91	1.1	13
282	Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. <b>2010</b> , 115, 4651-6		99
281	A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. <b>2010</b> , 116, 893-9		124
280	Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. <b>2010</b> , 116, 4095-8		132
279	An overview on bone manifestations in Gaucher disease. <b>2010</b> , 160, 609-24		62
278	The role of ADAMTSs in arthritis. <b>2010</b> , 1, 33-47		61
277	Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk. <b>2010</b> , 32, 2048-52		11
276	Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease. <i>British Journal of Haematology</i> , <b>2010</b> , 150, 93-101	4-5	22
275	Velaglucerase alfa. <b>2010</b> , 9, 837-8		23
274	Optimal therapy in Gaucher disease. <b>2010</b> , 6, 315-23		13
273	Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. <b>2010</b> , 5, e10750		34
272	Gaucher disease: clinical profile and therapeutic developments. <i>Biologics: Targets and Therapy</i> , <b>2010</b> , 4, 299-313	4-4	79
271	The management of Gaucher disease in developing countries: a successful experience in Southern Brazil. <b>2010</b> , 13, 27-33		3
270	Enzyme replacement therapy in type 1 Gaucher disease and a review of the literature. <b>2010</b> , 27, 190-5		1

269	Therapeutic goals in the treatment of Fabry disease. <i>Genetics in Medicine</i> , <b>2010</b> , 12, 713-20	8.1	26
268	Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease. <b>2010</b> , 24, 41-7		26
267	Platelet-Vessel Wall Interactions in Hemostasis and Thrombosis. <b>2010</b> , 2, 1-75		31
266	Pediatric Gaucher disease type I and mild growth hormone deficiency: a new feature?. <b>2010</b> , 33 Suppl 3, S51-4		59
265	The glomerulus--a view from the inside--the endothelial cell. <b>2010</b> , 42, 1388-97		47
264	Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1. <b>2010</b> , 21, 104-13		4
263	Proteinase-activated receptor (PAR1) polymorphic variant correlates with thrombocytopenia in Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , <b>2010</b> , 44, 79-81	2.1	2
262	Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study. <i>Blood Cells, Molecules, and Diseases</i> , <b>2010</b> , 44, 181-7	2.1	12
261	Thrombotic thrombocytopenic purpura as the first manifestation of metastatic adenocarcinoma in a young woman. <b>2010</b> , 42, 39-42		9
260	Postoperative thrombotic thrombocytopenic purpura after open heart operations. <b>2010</b> , 89, 119-23		32
259	A validated disease severity scoring system for adults with type 1 Gaucher disease. <i>Genetics in Medicine</i> , <b>2010</b> , 12, 44-51	8.1	51
258	Maladie de Gaucher: diagnostic, suivi et traitement. <i>Revue Du Rhumatisme Monographies</i> , <b>2011</b> , 78, 246-253		
257	Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. <b>2011</b> , 118, 5767-73		157
256	Analysis of glucocerebrosidase activity in dry blood spots using tandem mass spectrometry. <b>2011</b> , 412, 343-6		15
255	Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States. <b>2011</b> , 17, 674-81		18
254	Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , <b>2011</b> , 46, 119-23	2.1	30
253	Whole body MRI in type I Gaucher patients: evaluation of skeletal involvement. <i>Blood Cells, Molecules, and Diseases</i> , <b>2011</b> , 46, 53-9	2.1	20
252	Improving the accuracy of MRI spleen and liver volume measurements: a phase III Gaucher disease clinical trial setting as a model. <i>Blood Cells, Molecules, and Diseases</i> , <b>2011</b> , 46, 47-52	2.1	14

251	Potential biomarkers of osteonecrosis in Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , <b>2011</b> , 46, 27-33	2.1	37
250	Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction. <i>Blood Cells, Molecules, and Diseases</i> , <b>2011</b> , 47, 56-61	2.1	30
249	A novel tool for mapping disease severity and outcomes in patients with Gaucher disease utilising the therapeutic goals. <i>Molecular Genetics and Metabolism</i> , <b>2011</b> , 102, S46	3.7	
248	Agalsidase Alfa and Agalsidase beta Have Similar Effects on Outcomes in Fabry disease—results from the canadian Fabry disease initiative. <i>Molecular Genetics and Metabolism</i> , <b>2011</b> , 102, S46	3.7	3
247	Few females develop anti-β-galactosidase A IgG antibodies in response to agalsidase beta treatment: data from the Fabry Registry. <i>Molecular Genetics and Metabolism</i> , <b>2011</b> , 102, S46-S47	3.7	2
246	Therapeutic approaches to bone pathology in Gaucher disease: past, present and future. <i>Molecular Genetics and Metabolism</i> , <b>2011</b> , 104, 438-47	3.7	46
245	Gaucher's disease: the changing paradigm of a lysosomal disorder. <b>2011</b> , 137 Suppl 1, 3-5		
244	[Clinical outcomes of 2 pediatric patients with Gaucher's disease in enzyme replacement therapy for 9 years]. <b>2011</b> , 137 Suppl 1, 43-5		
243	[Therapeutic targets in Gaucher's disease]. <b>2011</b> , 137 Suppl 1, 46-9		5
242	[Guidelines for type 1 Gaucher's disease]. <b>2011</b> , 137 Suppl 1, 55-60		7
241	Prevalence and management of Gaucher disease. <b>2011</b> , 59		3
240	Imaging findings in pediatric type 1 Gaucher disease: what the clinician needs to know. <b>2011</b> , 33, 301-5		2
239	Velaglucerase alfa as a therapeutic option for Gaucher disease. <b>2011</b> , 6, 13-20		
238	Velaglucerase alfa in the treatment of Gaucher disease type 1. <b>2011</b> , 1, 285-293		23
237	Individualized long-term enzyme therapy for Gaucher disease type 1 in Slovenia. <b>2011</b> , 53, 1018-22		1
236	Miscellaneous non-inflammatory musculoskeletal conditions. Gaucher disease and bone. <b>2011</b> , 25, 665-81		24
235	Pharmacological chaperone therapy for Gaucher disease: a patent review. <b>2011</b> , 21, 885-903		94
234	Neurological manifestations in patients with Gaucher disease and their relatives, it is just a coincidence?. <b>2011</b> , 34, 781-7		14

233	Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibobodies. <b>2011</b> , 34, 605-19		80
232	Gastrointestinal disturbances and their management in miglustat-treated patients. <b>2011</b> , 34, 991-1001		55
231	Vertebral fractures in Gaucher disease type I: data from the French "Observatoire" on Gaucher disease (FROG). <b>2011</b> , 22, 1255-61		14
230	Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience. <b>2011</b> , 93, 163-169		26
229	Reducing selection bias in case-control studies from rare disease registries. <i>Orphanet Journal of Rare Diseases</i> , <b>2011</b> , 6, 61	4.2	17
228	A reappraisal of Gaucher disease-diagnosis and disease management algorithms. <i>American Journal of Hematology</i> , <b>2011</b> , 86, 110-5	7.1	98
227	Organ volume by computed tomography correlates with longitudinal axis on ultrasound in patients with Gaucher disease. <b>2011</b> , 27, 225-8		7
226	Glycomics. <b>2011</b> , 427-446		
225	How I treat Gaucher disease. <b>2011</b> , 118, 1463-71		114
224	Systemic lupus erythematosus presenting as thrombotic thrombocytopenia purpura: how close is close enough?. <b>2011</b> , 2011, 267508		6
223	Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13. <b>2012</b> , 6, e1628		40
222	Outcome and relapse risks of thrombotic thrombocytopenic purpura: an Egyptian experience. <b>2012</b> , 88, 433-6		1
221	The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. <b>2012</b> , 16, 1-543		78
220	Congenital thrombotic thrombocytopenic purpura associated with moyamoya syndrome in a 3-year-old girl: a case report. <b>2012</b> , 27, 1331-5		0
219	Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 Italian Gaucher type I patients. <b>2013</b> , 7, 117-22		18
218	Minimal disease activity in Gaucher disease: criteria for definition. <i>Molecular Genetics and Metabolism</i> , <b>2012</b> , 107, 521-5	3.7	4
217	Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem. <i>Blood Cells, Molecules, and Diseases</i> , <b>2012</b> , 48, 45-50	2.1	19
216	Acupuncture for symptoms of Gaucher disease. <b>2012</b> , 20, 131-4		5

215	Initiation treatment with imiglucerase every 3 weeks in type 1 Gaucher disease. <b>2012</b> , 23, e71-2		
214	Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula. <i>Orphanet Journal of Rare Diseases</i> , <b>2012</b> , 7, 17	4.2	33
213	Overview and Classification of Approved Recombinant Drugs. <b>2012</b> , 153-178		2
212	Increased ADAMTS13 activity in patients with venous thromboembolism. <i>Thrombosis Research</i> , <b>2012</b> , 130, 889-93	8.2	22
211	Endothelial cells and thrombotic microangiopathy. <b>2012</b> , 32, 208-14		15
210	Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study. <i>Orphanet Journal of Rare Diseases</i> , <b>2012</b> , 7, 102	4.2	38
209	Sequential occurrence of thrombotic thrombocytopenic purpura, essential thrombocythemia, and idiopathic thrombocytopenic purpura in a 42-year-old African-American woman: a case report and review of the literature. <b>2012</b> , 6, 93		6
208	Indicators of acute and persistent renal damage in adult thrombotic microangiopathy. <b>2012</b> , 7, e30886		10
207	Imiglucerase in the treatment of Gaucher disease: a history and perspective. <b>2012</b> , 6, 81-106		25
206	Bone turnover markers in patients with type 1 Gaucher disease. <b>2012</b> , 4, e21		17
205	South African guidelines for the management of Gaucher disease, 2011. <b>2012</b> , 102, 697-702		1
204	Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. <b>2012</b> , 27, 1839-48		64
203	Velaglucerase alfa for the management of type 1 Gaucher disease. <b>2012</b> , 34, 259-71		15
202	Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W. <b>2012</b> , 10, 940-50		17
201	Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years. <i>British Journal of Haematology</i> , <b>2012</b> , 158, 528-38	4.5	28
200	Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review. <b>2013</b> , 10, 34		18
199	JIMD Reports - Case and Research Reports, 2012/4. <b>2013</b> ,		
198	Revised recommendations for the management of Gaucher disease in children. <b>2013</b> , 172, 447-58		64

197	Safety and efficacy of velaglucerase alfa replacement therapy for patients with type 1 Gaucher disease. <b>2013</b> , 8, 333-339		
196	Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. <i>Blood Cells, Molecules, and Diseases</i> , <b>2013</b> , 51, 116-24	2.1	51
195	Thrombotic thrombocytopenic purpura (TTP) leading to pseudotumour's autoimmune pancreatitis (AIP): a case report. <b>2013</b> , 13, 90-4		4
194	Co hematolog powinien wiedzieć chorobie Gauchera. <b>2013</b> , 44, 301-306		8
193	Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. <i>British Journal of Haematology</i> , <b>2013</b> , 161, 832-42	4.5	84
192	Enzyme replacement and substrate reduction therapy for Gaucher disease. <b>2013</b> ,		1
191	Assessment of individual organs: other organs. <b>2013</b> , 202-213		
190	Haematological manifestations and complications of Gaucher disease. <b>2013</b> , 20, 41-7		13
189	Achievement of therapeutic goals with low-dose imiglucerase in Gaucher disease: a single-center experience. <b>2013</b> , 2013, 151506		7
188	The importance of patient registries for rare diseases. <b>2013</b> , 1, 769-772		5
187	Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 172-8	7.1	43
186	Gauchers disease--a reappraisal of hematopoietic stem cell transplantation. <b>2013</b> , 30, 61-70		22
185	A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients. <b>2013</b> , 8, e69293		21
184	Gaucher disease: a comprehensive review. <b>2013</b> , 18, 163-75		91
183	Management of bone disease in Gaucher disease type 1: clinical practice. <b>2014</b> , 31, 1197-212		21
182	Early diagnosis of Gaucher disease in pediatric patients: proposal for a diagnostic algorithm. <b>2014</b> , 61, 1905-9		25
181	Eliglustat tartrate: an oral therapeutic option for Gaucher disease type 1. <b>2014</b> , 4, 45-53		2
180	Hemorrhagic aspects of Gaucher disease. <b>2014</b> , 5, e0039		14

179	Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. <i>Blood Cells, Molecules, and Diseases</i> , <b>2014</b> , 53, 274-6	2.1	58
178	Gaucher disease. <b>2014</b> , 4, 37-50		57
177	High frequency of acquired ADAMTS13 deficiency after hemolysis in Hemiscorpius Lepturus (scorpion) stung children. <b>2014</b> , 81, 665-9		7
176	Gaucher disease: haematological presentations and complications. <i>British Journal of Haematology</i> , <b>2014</b> , 165, 427-40	4.5	68
175	Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up. <i>Blood Cells, Molecules, and Diseases</i> , <b>2014</b> , 53, 56-60	2.1	12
174	Gaucher disease: a diagnostic challenge for internists. <b>2014</b> , 25, 117-24		29
173	Biotransformation of Waste Biomass into High Value Biochemicals. <b>2014</b> ,		29
172	Gaucher disease and bone manifestations. <b>2014</b> , 95, 477-94		40
171	Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications. <i>Orphanet Journal of Rare Diseases</i> , <b>2014</b> , 9, 112	4.2	29
170	Evoluci3n cl3nica y paracl3nica de 9 embarazos en 4 pacientes con enfermedad de Gaucher tipo 1 en el servicio de hematolog3a de un hospital docente asistencial. <b>2014</b> , 57, 362-367		
169	Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study. <b>2014</b> , 37, 961-8		6
168	Development and application to clinical practice of a validated HPLC method for the analysis of Bglucocerebrosidase in Gaucher disease. <b>2014</b> , 91, 123-30		5
167	A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. <i>Blood Cells, Molecules, and Diseases</i> , <b>2014</b> , 53, 253-60	2.1	44
166	Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients. <i>Molecular Genetics and Metabolism</i> , <b>2014</b> , 113, 213-8	3.7	21
165	The various states of von Willebrand factor and their function in physiology and pathophysiology. <b>2014</b> , 111, 598-609		61
164	Long-term treatment outcomes in Gaucher disease. <i>American Journal of Hematology</i> , <b>2015</b> , 90 Suppl 1, S19-24	7.1	34
163	Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry. <i>American Journal of Hematology</i> , <b>2015</b> , 90 Suppl 1, S12-8	7.1	63
162	Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 592-7	7.1	11

161	Understanding the natural history of Gaucher disease. <i>American Journal of Hematology</i> , <b>2015</b> , 90 Suppl 1, S6-11	7.1	51
160	von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. <b>2015</b> , 125, 3153-63		86
159	Gaucher's disease: report of 11 cases with review of literature. <b>2015</b> , 20, 18		10
158	Clinical manifestations and management of Gaucher disease. <b>2015</b> , 12, 157-64		36
157	Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. <b>2015</b> , 385, 2355-62		106
156	The history and accomplishments of the ICGG Gaucher registry. <i>American Journal of Hematology</i> , <b>2015</b> , 90 Suppl 1, S2-5	7.1	14
155	Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 577-83	7.1	18
154	Management of women with Gaucher disease in the reproductive age. <i>Thrombosis Research</i> , <b>2015</b> , 135 Suppl 1, S49-51	8.2	9
153	Zarys objawów klinicznych, leczenia oraz trudności w rozpoznawaniu choroby Gauchera. <b>2015</b> , 46, 149-157		2
152	Quantification of Bone Marrow Involvement in Treated Gaucher Disease With Proton MR Spectroscopy: Correlation With Bone Marrow MRI Scores and Clinical Status. <b>2015</b> , 204, 1296-302		12
151	The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease. <b>2015</b> , 29, 205-18		14
150	Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1. <i>Orphanet Journal of Rare Diseases</i> , <b>2015</b> , 10, 62	4.2	6
149	Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 584-91	7.1	28
148	Eliglustat: A Review in Gaucher Disease Type 1. <b>2015</b> , 75, 1669-78		24
147	Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency. <i>Molecular Genetics and Metabolism</i> , <b>2015</b> , 116, 88-97	3.7	58
146	Stellungnahme der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Eliglustat [Nutzenbewertung gemäß § 35a SGB V des G-BA. <b>2015</b> , 53, 1027-1033		
145	Absolute immature platelet count dynamics in diagnosing and monitoring the clinical course of thrombotic thrombocytopenic purpura. <b>2015</b> , 55, 756-65		22
144	Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options. <b>2016</b> , 51, 553-63		26

143	Profile of eliglustat tartrate in the management of Gaucher disease. <b>2016</b> , 12, 53-8		12
142	Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy. <b>2016</b> , 11, 37-47		12
141	Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. <b>2016</b> , 11, e0168135		22
140	Treatment options for patients with Gaucher disease. <b>2016</b> , 17, 281-285		10
139	Outcome of Gaucher Disease in India: Lessons from Prevalent Diagnostic and Therapeutic Practices. <b>2016</b> , 53, 685-8		1
138	Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial. <i>Molecular Genetics and Metabolism Reports</i> , <b>2016</b> , 9, 25-28	1.8	6
137	Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 656-60	7.1	14
136	Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 661-5	7.1	16
135	Evaluation of Bone Mineral Density in Patients with Type 1 Gaucher Disease in Argentina. <b>2016</b> , 19, 444-449		
134	Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients. <i>American Journal of Hematology</i> , <b>2016</b> , 91, E448-53	7.1	11
133	Rare Case of Hepatic Gaucheroma in a Child on Enzyme Replacement Therapy. <b>2017</b> , 32, 101-104		5
132	Cellular Uptake of Glucocerebrosidase in Gaucher Patients Receiving Enzyme Replacement Treatment. <b>2016</b> , 55, 1103-13		2
131	Rethinking fatigue in Gaucher disease. <i>Orphanet Journal of Rare Diseases</i> , <b>2016</b> , 11, 53	4.2	9
130	Gaucher disease causing sudden cardiac death. <b>2016</b> , 68, 201-204		0
129	Comparison of Bone Mineral Density by Dual-Energy X-Ray Absorptiometry and Bone Strength by Speed-of-Sound Ultrasonography in Adults With Gaucher Disease. <b>2016</b> , 19, 465-470		1
128	Pleural tuberculosis in a patient with untreated type 1 Gaucher disease. <b>2016</b> , 22, 53-7		1
127	Characterization of the complex formed by $\beta$ -glucocerebrosidase and the lysosomal integral membrane protein type-2. <b>2016</b> , 113, 3791-6		33
126	Hematological manifestations and complications of Gaucher disease. <b>2016</b> , 9, 51-8		18

125	Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. <i>Molecular Genetics and Metabolism</i> , <b>2016</b> , 117, 95-103	3.7	44
124	Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status. <i>Blood Cells, Molecules, and Diseases</i> , <b>2016</b> , 56, 23-30	2.1	21
123	Dynamic changes in absolute immature platelet count suggest the presence of a coexisting immune process in the setting of thrombotic thrombocytopenic purpura. <b>2017</b> , 57, 913-918		7
122	Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. <i>Molecular Genetics and Metabolism</i> , <b>2017</b> , 120, 47-56	3.7	33
121	JIMD Reports, Volume 32. <b>2017</b> ,		
120	Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. <b>2017</b> , 129, 2375-2383		40
119	A comparison study of bioanalytical methods for detection and characterization of anti-velaglucerase alfa antibodies. <b>2017</b> , 9, 775-786		1
118	Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 929-939	7.1	23
117	Gaucher disease: risk stratification and comorbidities. <b>2017</b> , 5, 839-846		
116	Treatment of profound thrombocytopenia in a patient with Gaucher disease type 1: Is there a role for substrate reduction therapy. <i>Molecular Genetics and Metabolism Reports</i> , <b>2017</b> , 12, 82-84	1.8	3
115	Letter to the Editor on "Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options". <b>2017</b> , 52, 725-726		
114	Gaucher Disease and Hurler Syndrome in Two First Cousins. <b>2017</b> , 17, 109-117		2
113	Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease. <i>Orphanet Journal of Rare Diseases</i> , <b>2017</b> , 12, 84	4.2	17
112	Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. <b>2017</b> , 37, 25-32		42
111	Choroba Gauchera - zalecenia dotyczce rozpoznawania, leczenia i monitorowania. <b>2017</b> , 48, 222-261		
110	A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	298
109	Glycomics. <b>2017</b> , 413-434		
108	Chronic pain in Gaucher disease: skeletal or neuropathic origin?. <i>Orphanet Journal of Rare Diseases</i> , <b>2017</b> , 12, 148	4.2	9

107	Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial. <i>Molecular Genetics and Metabolism</i> , <b>2018</b> , 123, 347-356	3-7	11
106	Recent advances in the diagnosis and management of Gaucher disease. <b>2018</b> , 13, 107-118		41
105	Complications of Implanted Nonbiologic Devices-An Overview. <b>2018</b> , 44, 7-11		2
104	Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months. <b>2018</b> , 41, 829-838		49
103	Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I. <b>2018</b> , 123, 65-71		3
102	Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. <i>Blood Cells, Molecules, and Diseases</i> , <b>2018</b> , 71, 71-74	2.1	20
101	Genetic and clinical characteristics of Filipino patients with Gaucher disease. <i>Molecular Genetics and Metabolism Reports</i> , <b>2018</b> , 15, 110-115	1.8	4
100	Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey. <i>Blood Cells, Molecules, and Diseases</i> , <b>2018</b> , 68, 218-225	2.1	8
99	Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , <b>2018</b> , 68, 203-208	2.1	49
98	Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials. <i>Blood Cells, Molecules, and Diseases</i> , <b>2018</b> , 68, 153-159	2.1	12
97	Liver involvement in Gaucher disease - Review and clinical approach. <i>Blood Cells, Molecules, and Diseases</i> , <b>2018</b> , 68, 66-73	2.1	23
96	Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project. <i>Blood Cells, Molecules, and Diseases</i> , <b>2018</b> , 68, 173-179	2.1	15
95	A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration. <i>Blood Cells, Molecules, and Diseases</i> , <b>2018</b> , 68, 185-191	2.1	31
94	Growth and final height of children with Gaucher disease: A 15-year follow-up at an Israeli Gaucher center. <i>Blood Cells, Molecules, and Diseases</i> , <b>2018</b> , 68, 97-99	2.1	8
93	The role of high density lipoprotein in Type 1 Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , <b>2018</b> , 68, 43-46	2.1	4
92	Skeletal involvement in type 1 Gaucher disease: Not just bone mineral density. <i>Blood Cells, Molecules, and Diseases</i> , <b>2018</b> , 68, 148-152	2.1	18
91	Enzyme Replacement Therapy in a Gaucher Family. <i>Journal of the National Medical Association</i> , <b>2018</b> , 110, 330-333	2.3	3
90	Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS). <i>American Journal of Hematology</i> , <b>2018</b> , 93, 205-212	7.1	28

89	Recent advances and future challenges in Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , <b>2018</b> , 68, 9-13	2.1	3
88	Lysosomal storage disease overview. <i>Annals of Translational Medicine</i> , <b>2018</b> , 6, 476	3.2	90
87	Pharmacological treatment of pediatric Gaucher disease. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 1183-1194	3.8	11
86	Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2018</b> , 24, 1002-1008	1.9	6
85	How we manage Gaucher Disease in the era of choices. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 467-480	4.5	50
84	The Importance of a Multidisciplinary Approach in the Management of a Patient with Type I Gaucher Disease. <i>Diseases (Basel, Switzerland)</i> , <b>2018</b> , 6,	4.4	4
83	22 Retinal Manifestations of Metabolic Disease. <b>2018</b> ,		
82	Very rare condition of multiple Gaucheroma: A case report and review of the literature. <i>Molecular Genetics and Metabolism Reports</i> , <b>2019</b> , 20, 100489	1.8	1
81	Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement. <i>Insights Into Imaging</i> , <b>2019</b> , 10, 70	5.6	6
80	[Diagnostic journey of type 1 Gaucher Disease patients: A survey including internists and hematologists]. <i>Revue De Medecine Interne</i> , <b>2019</b> , 40, 778-784	0.1	2
79	Population-based cohort of 500 patients with Gaucher disease in Israel. <i>BMJ Open</i> , <b>2019</b> , 9, e024251	3	5
78	Absolute immature platelet count dynamics of thrombotic thrombocytopenic purpura patients with high ADAMTS13 inhibitor. <i>Thrombosis Research</i> , <b>2019</b> , 179, 128-131	8.2	6
77	Very rare condition of multiple Gaucheroma: A case report and review of the literature. <i>Molecular Genetics and Metabolism Reports</i> , <b>2019</b> , 20, 100473	1.8	7
76	A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease. <i>Biochemical Pharmacology</i> , <b>2019</b> , 164, 188-204	6	38
75	Manifestations osseuses de la maladie de Gaucher. <i>Revue Du Rhumatisme Monographies</i> , <b>2019</b> , 86, 100-107		
74	Current and Emerging Pharmacotherapy for Gaucher Disease. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , <b>2019</b> , 17, 142-151	2.5	0
73	Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review. <i>Orphanet Journal of Rare Diseases</i> , <b>2019</b> , 14, 275	4.2	7
72	Glycoprotein Non-Metastatic Protein B: An Emerging Biomarker for Lysosomal Dysfunction in Macrophages. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 20,	6.3	30

71	Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 29-38	7.1	27
70	Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease. <i>Neurobiology of Disease</i> , <b>2019</b> , 122, 72-82	7.5	37
69	Controlled attenuation parameter and liver stiffness measurements using transient elastography by FibroScan in Gaucher disease. <i>Molecular Genetics and Metabolism</i> , <b>2020</b> , 129, 125-131	3.7	3
68	Platelet function defects in patients with Gaucher disease on long term ERT- implications for evaluation at bleeding challenges. <i>Blood Cells, Molecules, and Diseases</i> , <b>2020</b> , 80, 102371	2.1	2
67	Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy. <i>Molecular Genetics and Metabolism</i> , <b>2020</b> , 131, 116-123	3.7	2
66	Spectrum of Lysosomal Storage Disorders at Tertiary Centre: Retrospective Case-Record Analysis. <i>Journal of Pediatric Genetics</i> , <b>2020</b> , 9, 87-92	0.7	2
65	Downregulation of B regulatory cells and upregulation of T helper 1 cells in children with Gaucher disease undergoing enzyme replacement therapy. <i>Immunologic Research</i> , <b>2020</b> , 68, 73-80	4.3	2
64	Quality of life and psychological functioning of pediatric and young adult patients with Gaucher disease, type 1. <i>American Journal of Medical Genetics, Part A</i> , <b>2020</b> , 182, 1130-1142	2.5	3
63	The N370S/R496H genotype in type 1 Gaucher disease - Natural history and implications for pre symptomatic diagnosis and counseling. <i>Molecular Genetics and Metabolism Reports</i> , <b>2020</b> , 22, 100567	1.8	2
62	Nutrition in adult patients with selected lysosomal storage diseases. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2021</b> , 31, 733-744	4.5	3
61	Lysosomal Storage Disorders. <b>2021</b> , 563-682		2
60	The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients. <i>Orphanet Journal of Rare Diseases</i> , <b>2021</b> , 16, 92	4.2	1
59	Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes. <i>Molecular Genetics and Metabolism</i> , <b>2021</b> , 132, 49-58	3.7	6
58	Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. <i>Molecular Genetics and Metabolism</i> , <b>2021</b> , 132, 100-111	3.7	6
57	Screening for Gaucher Disease Using Dried Blood Spot Tests: A Japanese Multicenter, Cross-sectional Survey. <i>Internal Medicine</i> , <b>2021</b> , 60, 699-707	1.1	3
56	One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency. <i>Genetics in Medicine</i> , <b>2021</b> , 23, 1543-1550	8.1	9
55	Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation. <i>Orphanet Journal of Rare Diseases</i> , <b>2021</b> , 16, 212	4.2	1
54	Clinical and radiological evaluation of dentomaxillofacial involvement in Type I Gaucher disease. <i>Oral Radiology</i> , <b>2021</b> , 1	2.5	1

53	Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 1156-1165	7.1	3
52	Metabolizing profile of the cytochrome pathway CYP2D6, CYP3A4 and the ABCB 1 transporter in Spanish patients affected by Gaucher disease. <i>Chemico-Biological Interactions</i> , <b>2021</b> , 345, 109527	5	
51	Bone marrow burden score is not useful as a follow-up parameter in stable patients with type 1 Gaucher disease after 5 years of treatment. <i>Blood Cells, Molecules, and Diseases</i> , <b>2021</b> , 90, 102591	2.1	0
50	Clinical-genetic characteristics and treatment outcomes of Turkish children with Gaucher disease type 1 and type 3: A sixteen year single-center experience. <i>European Journal of Medical Genetics</i> , <b>2021</b> , 64, 104339	2.6	0
49	Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease. <i>Molecular Genetics and Metabolism Reports</i> , <b>2021</b> , 29, 100798	1.8	1
48	Gaucher Disease. 47-57		1
47	Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1038-1046	7.1	10
46	Lysosomal Storage Diseases. <b>2012</b> , 403-451		2
45	Doença de Gaucher: uma desordem subdiagnosticada. <i>Revista Paulista De Pediatria</i> , <b>2011</b> , 29, 122-125	1.2	1
44	DOENÇA DE GAUCHER TIPO 1 NO ESQUELETO: REVISÃO DA AMÉRICA LATINA. <i>Coluna/ Columna</i> , <b>2016</b> , 15, 317-324	0.2	1
43	Treatment for Lysosomal Storage Disorders. <i>Current Pharmaceutical Design</i> , <b>2020</b> , 26, 5110-5118	3.3	2
42	The Clinical Efficacy of Imiglucerase versus Eliglustat in Patients with Gaucher's Disease Type 1: A Systematic Review. <i>Journal of Research in Pharmacy Practice</i> , <b>2018</b> , 7, 171-177	1.3	2
41	Diagnosis and management of hematological manifestations of gaucher disease: Insights from Saudi Arabia. <i>Journal of Applied Hematology</i> , <b>2021</b> , 12, 123	0.4	
40	In-depth phenotyping for clinical stratification of Gaucher disease. <i>Orphanet Journal of Rare Diseases</i> , <b>2021</b> , 16, 431	4.2	1
39	Gaucher Disease. <b>2008</b> , 1548-1557		
38	Proteins: Hormones, Enzymes, and Monoclonal Antibodies Background. 1		
37	Pulmonary Arterial Hypertension Related to Gaucher's Disease, Sarcoidosis, and Other Disorders. <b>2011</b> , 1061-1081		1
36	Gaucher's disease. <b>2011</b> , 2031-2036		

35	Alternative Treatment Options: Enzyme Replacement and Small Molecule Therapies. <i>Pancreatic Islet Biology</i> , <b>2013</b> , 21-35	0.4	
34	Pharmaceutical Enzymes. <b>2014</b> , 367-387		2
33	Lysosomal Storage Disorders Including Neuronal Ceroid Lipofuscinoses. <b>2014</b> , 399-435		
32	Encyclopedia of Inflammatory Diseases. <b>2015</b> , 1-8		
31	Gaucher disease. <b>2015</b> , 1705-1710		
30	Gaucher Disease. <b>2016</b> , 501-508		
29	Lysosomal Storage Disorders: Haematology Perspective. <b>2016</b> , 619-631		
28	Enzyme Replacement Therapy. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , <b>2018</b> , 1-22	0.3	
27	Gaucher disease and liver involvement: A review and our experience. <i>Annals of Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 3, 031-034	0.2	
26	Focused Ultrasound Mediated Opening of the Blood-Brain Barrier for Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 749047	4.1	5
25	Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. <i>Biologics: Targets and Therapy</i> , <b>2009</b> , 3, 407-17	4.4	34
24	Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history. <i>Pediatric Endocrinology Reviews</i> , <b>2014</b> , 12 Suppl 1, 72-81	1.1	30
23	Pharmacotherapy of Gaucher Disease: Current and Future Options. <i>P and T</i> , <b>2018</b> , 43, 274-309	1.4	4
22	A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , <b>2021</b> , 15, 747726	5.1	
21	A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , <b>2021</b> , 15, 747726	5.1	2
20	Quantitative assessment of the exposure-efficacy relationship of glucocerebrosidase using Markovian elements in Gaucher patients treated with enzyme replacement therapy.. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	
19	Lipidoses: The Sphingolipidoses, Lysosomal Acid Lipase Deficiency, and Niemann-Pick Type C. <b>2022</b> , 1177-1206		0
18	The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?. <i>Molecular Genetics and Metabolism</i> , <b>2022</b> ,	3.7	1

17	Gaucher's disease. <i>Eksperimentalnaya I Klinicheskaya Gastroenterologiya</i> , <b>2021</b> , 147-154	0.4	
16	Novel Management and Screening Approaches for Haematological Complications of Gaucher's Disease.. <i>Journal of Blood Medicine</i> , <b>2021</b> , 12, 1045-1056	2.3	1
15	A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results.. <i>Genetics in Medicine</i> , <b>2022</b> ,	8.1	0
14	Recomendaciones para el tratamiento oral de pacientes adultos con enfermedad de Gaucher tipo 1. <i>Revista Clinica Espanola</i> , <b>2022</b> ,	0.7	
13	Update of treatment for Gaucher disease.. <i>European Journal of Pharmacology</i> , <b>2022</b> , 926, 175023	5.3	2
12	The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States. <i>Journal of Medical Economics</i> , 1-11	2.4	2
11	Recommendations for oral treatment for adult patients with type 1 Gaucher disease. <i>Revista Cl&amp;#x00ed;nica Espan&amp;#x00f5;la</i> , <b>2022</b> ,	0.5	
10	Gaucher Disease. <b>2022</b> , 85-97		
9	Biological Variation in Peripheral Inflammation and Oxidative Stress Biomarkers in Individuals with Gaucher Disease. <b>2022</b> , 23, 9189		0
8	Natural history and management of liver dysfunction in lysosomal storage disorders. 14, 1844-1861		0
7	Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.		1
6	Recommendations on the follow-up of patients with Gaucher disease in Spain: Results from a Delphi survey.		0
5	Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1. <b>2022</b> , 100329		0
4	Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results. <b>2022</b> , 17,		0
3	Utility of morphologic assessment of bone marrow biopsy in diagnosis of lysosomal storage disorders. <b>2023</b> , 66, 91		0
2	Gaucher Disease. <b>2023</b> , 1-6		0
1	High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy. <b>2023</b> , 24, 6732		0